Shares in PhaseBio Pharmaceuticals (PHAS) surged 82% in after-hours trading on Wednesday, after the company announced clearance of its investigational new drug (IND) application by the FDA under its Coronavirus Treatment Acceleration Program (CTAP).PhaseBio’s “VANGARD” trial will assess the efficacy and safety of its PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome. Approximately 210 patients will be targeted to be enrolled at approximately 20 sites across the US. The primary endpoint will measure days alive and free of respiratory failure.The patients will be treated with PB1046, a novel, once-weekly, subcutaneously-injected vasoactive …read more
Source:: Yahoo Finance
